Novo Nordisk A/S ADR (NVO)

$44.39 +0.51 (1.16%)
Market Cap 195.92B
Revenue (ttm) 46.79B
Net Income (ttm) 15.51B
EPS (ttm) N/A
PE Ratio 10.80
Forward PE 12.63
Profit Margin 33.14%
Debt to Equity Ratio 0.67
Volume 18,639,193
Avg Vol 21,395,635
Day's Range N/A - N/A
Shares Out 4.47B
Stochastic %K 97%
Beta 0.77
Analysts Sell
Price Target $45.66

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 45 44 44 88 88
Address:
Novo Alle 1, Bagsvaerd, Denmark
A_guys_Opinion
A_guys_Opinion May. 4 at 10:08 PM
$NVO I don’t like lly is having problems with their orforglipron pill in terms of side effects. I like the fact that the entirety of sell side analysts bragged about the drug non stop for a year straight just for anemic script volume vs oral semaglutide. Morons really looked at the fact that people have to fast 30 mins after taking it and automatically forecasted a 80/20 market share to Lilly. Don’t come running back now stay on your sinking ship sell side!
0 · Reply
Valconomics
Valconomics May. 4 at 10:08 PM
$NVO $LLY Novo Nordisk is led by idiots. Despite a record-breaking pipeline, the stock has tanked 50% from its highs just this past quarter because the CEO and CFO are too busy playing it "safe" with pathetic, negative guidance. The Reality vs. Management’s Stupidity: • Oral Wegovy is absolutely killing the inferior and dangerous "Foundayo." •:Novo’s U.S. market share actually increased from 39.1% to 39.4% in Q1. • 7.2 mg Wegovy approved in Europe and the US to go hand-in-hand against Lilly's Zepbound. • NHS Victory: The NHS approved Wegovy for both obesity and cardiovascular disease. • Innovation: released the once-a-week injectable for diabetes and have Oral Ozempic ready to go. It is criminal to provide -5% to -13% negative growth guidance when the business is booming. Eli Lilly's management has the spine to guide higher, why don't ours? These overly conservative "leaders" are single-handedly destroying shareholder value. Raise the guidance or GET OUT!
0 · Reply
FuegoFiesta
FuegoFiesta May. 4 at 10:06 PM
$SEIC $NVO $TEVA $BP tea
0 · Reply
FuegoFiesta
FuegoFiesta May. 4 at 9:31 PM
$NVO $VST $ON $RDW perhaps
0 · Reply
gemini06
gemini06 May. 4 at 9:10 PM
$NVO when 60+ so I can exit at cost 🥲
0 · Reply
Mambatrades08
Mambatrades08 May. 4 at 9:02 PM
$NVO single handedly carrying my portfolio lol
0 · Reply
StockMacroView
StockMacroView May. 4 at 8:49 PM
$NVO is reshaping the GLP-1 narrative. Oral Wegovy launched in Jan → rapid uptake, tens of thousands of patients already, many first-time users. Telehealth demand reportedly doubled early on. Vs $LLY oral rollout still slower (~20K starts, ~1K/day adds). $NVO leveraged $149/month pricing + near-injection efficacy + brand power to dominate early perception. Orals = market expansion, not just substitution. Still early, volatile, but direction is clear: the oral GLP-1 race is heating up fast. Free sharing and subscription 👉 @StockMacroView.
0 · Reply
Hooooooold
Hooooooold May. 4 at 8:42 PM
$NVO nice! Ozempic tablets are available in 1.5mg, 4mg, and 9mg doses, starting on 4 May and Novo Nordisk has also filed for FDA approval for a 25mg Ozempic tablet, with a decision expected by the end of 2026.
0 · Reply
Hooooooold
Hooooooold May. 4 at 8:36 PM
$NVO The three Catalent fill-finish sites acquired by [[Novo Nordisk]] (in Bloomington, IN; Brussels, Belgium; and Anagni, Italy) are designed to "significantly" increase manufacturing capacity for GLP-1 and diabetes treatments, supporting a portion of the 45.2 million people Novo Nordisk served globally in 2024
0 · Reply
LowerLimb
LowerLimb May. 4 at 8:35 PM
$NVO bought back my CCs, you can feel the energy shifting
0 · Reply
Latest News on NVO
Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

Mon, 04 May 2026 14:04:53 -0400 - 4 hours ago

Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

Mon, 04 May 2026 06:45:58 -0400 - 11 hours ago

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

2026-05-02T11:55:00.000Z - 2 days ago

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

Canada approves second generic version of Ozempic

Fri, 01 May 2026 15:50:56 -0400 - 3 days ago

Canada approves second generic version of Ozempic

Novo Nordisk (NVO) Launches Oral Ozempic for Type 2 Diabetes Patients

2026-05-01T18:02:00.000Z - 3 days ago

Novo Nordisk (NVO) Launches Oral Ozempic for Type 2 Diabetes Patients

Novo Nordisk Launches Ozempic Pill in U.S.

2026-05-01T16:29:33.000Z - 3 days ago

Novo Nordisk Launches Ozempic Pill in U.S.

Novo Nordisk rolls out Ozempic pill in the U.S.

2026-05-01T14:33:59.000Z - 3 days ago

Novo Nordisk rolls out Ozempic pill in the U.S.

Is It Too Late to Buy Novo Nordisk AS (NVO) After 4.8% Rally? GF Value Says Undervalued

2026-04-30T22:09:43.000Z - 3 days ago

Is It Too Late to Buy Novo Nordisk AS (NVO) After 4.8% Rally? GF Value Says Undervalued

Eli Lilly (LLY) and Novo Nordisk Surge Following FDA Proposal on GLP-1 Drugs

2026-04-30T16:55:31.000Z - 4 days ago

Eli Lilly (LLY) and Novo Nordisk Surge Following FDA Proposal on GLP-1 Drugs

FDA Proposal Targets Novo Nordisk and Eli Lilly's Weight Loss Drug Ingredients

2026-04-30T16:50:57.000Z - 4 days ago

FDA Proposal Targets Novo Nordisk and Eli Lilly's Weight Loss Drug Ingredients

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

Thu, 30 Apr 2026 11:02:15 -0400 - 4 days ago

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

US FDA proposes excluding weight-loss drugs from compounding list

Thu, 30 Apr 2026 09:54:13 -0400 - 4 days ago

US FDA proposes excluding weight-loss drugs from compounding list

More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says

2026-04-30T12:30:27.000Z - 4 days ago

More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says

WEBINAR INVITATION: Novo Resources Corp. Executive Co-Chairman to discuss the March Quarter Activities and Outlook

Thu, 30 Apr 2026 08:00:00 -0400 - 4 days ago

WEBINAR INVITATION: Novo Resources Corp. Executive Co-Chairman to discuss the March Quarter Activities and Outlook

Company Diary: Palantir, Novo Nordisk, IAG

2026-04-30T09:30:07.000Z - 4 days ago

Company Diary: Palantir, Novo Nordisk, IAG

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

Wed, 29 Apr 2026 08:27:32 -0400 - 5 days ago

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

Health Canada approves 1st generic version of Novo Nordisk's Ozempic

2026-04-28T21:34:46.000Z - 6 days ago

Health Canada approves 1st generic version of Novo Nordisk's Ozempic

Health Canada approves first generic version of Novo Nordisk's Ozempic

Tue, 28 Apr 2026 17:06:43 -0400 - 6 days ago

Health Canada approves first generic version of Novo Nordisk's Ozempic

Order Flows Signal Sector Rotation As Investment Shifts Beyond Technology

2026-04-28T19:35:01.000Z - 6 days ago

Order Flows Signal Sector Rotation As Investment Shifts Beyond Technology

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Tue, 28 Apr 2026 08:00:00 -0400 - 6 days ago

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial

Tue, 28 Apr 2026 02:03:04 -0400 - 6 days ago

Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial

Is This Deal a Game Changer for Novo Nordisk?

2026-04-28T00:30:00.000Z - 6 days ago

Is This Deal a Game Changer for Novo Nordisk?

Fast Track Designation Granted to Coramitug by FDA, Boosting Novo Nordisk (NVO)

2026-04-27T22:57:50.000Z - 6 days ago

Fast Track Designation Granted to Coramitug by FDA, Boosting Novo Nordisk (NVO)

NVO: Novo Nordisk Advances Coramitug for ATTR Amyloidosis Treatment

2026-04-27T21:52:20.000Z - 7 days ago

NVO: Novo Nordisk Advances Coramitug for ATTR Amyloidosis Treatment

Novo Nordisk A/S - share repurchase programme

Mon, 27 Apr 2026 04:56:00 -0400 - 7 days ago

Novo Nordisk A/S - share repurchase programme

Is It Too Late to Buy Novo Nordisk AS (NVO) After 6.9% Rally? GF Value Says Undervalued

2026-04-24T22:06:23.000Z - 10 days ago

Is It Too Late to Buy Novo Nordisk AS (NVO) After 6.9% Rally? GF Value Says Undervalued

Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake

Fri, 24 Apr 2026 14:18:22 -0400 - 10 days ago

Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake

Battle Of The Weight-Loss Pills Continues With A Shocking Twist

2026-04-24T14:10:06.000Z - 10 days ago

Battle Of The Weight-Loss Pills Continues With A Shocking Twist

Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children

Fri, 24 Apr 2026 09:32:52 -0400 - 10 days ago

Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children

Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch

2026-04-23T16:19:57.000Z - 11 days ago

Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch

Ozempic Oral Version Launch by Novo Nordisk Boosts GLP-1 Market

2026-04-23T15:33:26.000Z - 11 days ago

Ozempic Oral Version Launch by Novo Nordisk Boosts GLP-1 Market

Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?

2026-04-23T13:30:00.000Z - 11 days ago

Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?

Novo Nordisk Advances Ozempic Pill for Kids

2026-04-23T13:07:48.000Z - 11 days ago

Novo Nordisk Advances Ozempic Pill for Kids

Novo Nordisk (NVO) Plans U.S. Launch of Ozempic Pill Following Successful Trial

2026-04-23T12:59:13.000Z - 11 days ago

Novo Nordisk (NVO) Plans U.S. Launch of Ozempic Pill Following Successful Trial

NVO: Novo Nordisk Reports Positive Trial Results for Oral Semaglutide in Youth Diabetes

2026-04-23T12:51:19.000Z - 11 days ago

NVO: Novo Nordisk Reports Positive Trial Results for Oral Semaglutide in Youth Diabetes

Novo Nordisk's Oral Semaglutide Shows Superior Blood Sugar Control In Youth-Onset Type 2 Diabetes

2026-04-23T11:06:42.000Z - 11 days ago

Novo Nordisk's Oral Semaglutide Shows Superior Blood Sugar Control In Youth-Onset Type 2 Diabetes

The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

2026-04-23T10:16:26.000Z - 11 days ago

The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients

Thu, 23 Apr 2026 06:06:00 -0400 - 11 days ago

Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients

Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study

Thu, 23 Apr 2026 05:23:06 -0400 - 11 days ago

Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study

Novo Nordisk's oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

Thu, 23 Apr 2026 05:10:00 -0400 - 11 days ago

Novo Nordisk's oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

Novo Nordisk (NVO) Sees Increased Options Activity Amid Growing Market Interest

2026-04-22T14:57:45.000Z - 12 days ago

Novo Nordisk (NVO) Sees Increased Options Activity Amid Growing Market Interest

Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50

Tue, 21 Apr 2026 13:54:00 -0400 - 13 days ago

Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50

Amazon launches GLP-1 weight loss program, promising'fast, convenient' access

2026-04-21T17:24:27.000Z - 13 days ago

Amazon launches GLP-1 weight loss program, promising'fast, convenient' access

Amazon GLP-1 Program Pressures Hims & Hers Stock

2026-04-21T17:22:08.000Z - 13 days ago

Amazon GLP-1 Program Pressures Hims & Hers Stock

Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon.

2026-04-21T14:58:55.000Z - 13 days ago

Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon.

Positive Phase 3 Results for Novo Nordisk (NVO) in Sickle Cell Disease Treatment

2026-04-20T16:33:47.000Z - 14 days ago

Positive Phase 3 Results for Novo Nordisk (NVO) in Sickle Cell Disease Treatment

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

2026-04-20T16:14:45.000Z - 14 days ago

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

Positive Phase 3 Results for Novo Nordisk (NVO) Boost Outlook

2026-04-20T15:58:04.000Z - 14 days ago

Positive Phase 3 Results for Novo Nordisk (NVO) Boost Outlook

NVO: Positive Data from Novo Nordisk Impacts Agios Pharmaceuticals' Stock

2026-04-20T15:55:07.000Z - 14 days ago

NVO: Positive Data from Novo Nordisk Impacts Agios Pharmaceuticals' Stock

Novo Nordisk (NVO) Achieves Key Milestones in Etavopivat Sickle Cell Disease Trial

2026-04-20T12:55:57.000Z - 14 days ago

Novo Nordisk (NVO) Achieves Key Milestones in Etavopivat Sickle Cell Disease Trial

Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake

Apr 17, 2026, 12:04 PM EDT - 17 days ago

Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake

LLY

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds

Apr 16, 2026, 12:21 PM EDT - 18 days ago

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds

Novo Nordisk weight-loss drug shows liver benefits in mouse study

Apr 15, 2026, 7:28 AM EDT - 19 days ago

Novo Nordisk weight-loss drug shows liver benefits in mouse study

Novo Nordisk CEO: This is where science meets speed and scale

Apr 14, 2026, 2:48 PM EDT - 20 days ago

Novo Nordisk CEO: This is where science meets speed and scale

Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI

Apr 14, 2026, 9:11 AM EDT - 20 days ago

Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI

Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic.

Apr 14, 2026, 7:27 AM EDT - 20 days ago

Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic.

Novo Nordisk taps OpenAI to boost AI in drug development

Apr 14, 2026, 3:27 AM EDT - 20 days ago

Novo Nordisk taps OpenAI to boost AI in drug development

Novo Nordisk and OpenAI Partner to Speed Drug Discovery

Apr 14, 2026, 2:37 AM EDT - 20 days ago

Novo Nordisk and OpenAI Partner to Speed Drug Discovery

Novo Nordisk partners with OpenAI as AI drug discovery hopes mount

Apr 14, 2026, 2:20 AM EDT - 20 days ago

Novo Nordisk partners with OpenAI as AI drug discovery hopes mount

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

Apr 14, 2026, 2:04 AM EDT - 20 days ago

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered

Apr 14, 2026, 2:00 AM EDT - 20 days ago

Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered

LLY v. NVO: Weighing Who's Winning the GLP-1 Industry

Apr 12, 2026, 9:30 AM EDT - 22 days ago

LLY v. NVO: Weighing Who's Winning the GLP-1 Industry

LLY

Genetic variations linked to weight loss, side effects from GLP-1 drugs

Apr 10, 2026, 4:07 PM EDT - 24 days ago

Genetic variations linked to weight loss, side effects from GLP-1 drugs

LLY

Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

Apr 10, 2026, 2:38 AM EDT - 24 days ago

Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

LLY

Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment

Apr 9, 2026, 3:30 PM EDT - 25 days ago

Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment

Why Novo Nordisk's Weight Loss Pill Has Taken Off

Apr 7, 2026, 2:15 PM EDT - 27 days ago

Why Novo Nordisk's Weight Loss Pill Has Taken Off

Can Wegovy HD 7.2 mg drive Novo Nordisk's obesity drug rebound?

Apr 7, 2026, 10:39 AM EDT - 27 days ago

Can Wegovy HD 7.2 mg drive Novo Nordisk's obesity drug rebound?

Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S.

Apr 7, 2026, 8:15 AM EDT - 27 days ago

Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S.

Novo Nordisk launches higher-dose Wegovy in the United States

Apr 7, 2026, 8:03 AM EDT - 27 days ago

Novo Nordisk launches higher-dose Wegovy in the United States

Trump's Iran deadline, the Altman-Musk feud, Novo's Wegovy pill and more in Morning Squawk

Apr 7, 2026, 7:57 AM EDT - 27 days ago

Trump's Iran deadline, the Altman-Musk feud, Novo's Wegovy pill and more in Morning Squawk

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

Apr 7, 2026, 7:00 AM EDT - 27 days ago

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

Novo Nordisk A/S – Share repurchase programme

Apr 7, 2026, 6:46 AM EDT - 27 days ago

Novo Nordisk A/S – Share repurchase programme

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 4 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN BMY MRK

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 4 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN ABBV AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 4 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN BMY MRK

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 4 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN ABBV AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 4 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN BMY GILD GSK JNJ

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 4 weeks ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

LLY PFE

Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison

Apr 2, 2026, 8:00 AM EDT - 4 weeks ago

Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison

LLY

Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead

Apr 2, 2026, 7:28 AM EDT - 4 weeks ago

Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead

LLY

Novo VP Weighs In on Approval of Lilly's Obesity Pill

Apr 1, 2026, 5:14 PM EDT - 4 weeks ago

Novo VP Weighs In on Approval of Lilly's Obesity Pill

LLY

Pricing and availability of Novo, Lilly's weight-loss drugs

Apr 1, 2026, 3:07 PM EDT - 4 weeks ago

Pricing and availability of Novo, Lilly's weight-loss drugs

LLY

Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?

Apr 1, 2026, 7:29 AM EDT - 4 weeks ago

Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?

Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator

Apr 1, 2026, 4:47 AM EDT - 4 weeks ago

Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks

Mar 31, 2026, 7:05 PM EDT - 4 weeks ago

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks

A_guys_Opinion
A_guys_Opinion May. 4 at 10:08 PM
$NVO I don’t like lly is having problems with their orforglipron pill in terms of side effects. I like the fact that the entirety of sell side analysts bragged about the drug non stop for a year straight just for anemic script volume vs oral semaglutide. Morons really looked at the fact that people have to fast 30 mins after taking it and automatically forecasted a 80/20 market share to Lilly. Don’t come running back now stay on your sinking ship sell side!
0 · Reply
Valconomics
Valconomics May. 4 at 10:08 PM
$NVO $LLY Novo Nordisk is led by idiots. Despite a record-breaking pipeline, the stock has tanked 50% from its highs just this past quarter because the CEO and CFO are too busy playing it "safe" with pathetic, negative guidance. The Reality vs. Management’s Stupidity: • Oral Wegovy is absolutely killing the inferior and dangerous "Foundayo." •:Novo’s U.S. market share actually increased from 39.1% to 39.4% in Q1. • 7.2 mg Wegovy approved in Europe and the US to go hand-in-hand against Lilly's Zepbound. • NHS Victory: The NHS approved Wegovy for both obesity and cardiovascular disease. • Innovation: released the once-a-week injectable for diabetes and have Oral Ozempic ready to go. It is criminal to provide -5% to -13% negative growth guidance when the business is booming. Eli Lilly's management has the spine to guide higher, why don't ours? These overly conservative "leaders" are single-handedly destroying shareholder value. Raise the guidance or GET OUT!
0 · Reply
FuegoFiesta
FuegoFiesta May. 4 at 10:06 PM
$SEIC $NVO $TEVA $BP tea
0 · Reply
FuegoFiesta
FuegoFiesta May. 4 at 9:31 PM
$NVO $VST $ON $RDW perhaps
0 · Reply
gemini06
gemini06 May. 4 at 9:10 PM
$NVO when 60+ so I can exit at cost 🥲
0 · Reply
Mambatrades08
Mambatrades08 May. 4 at 9:02 PM
$NVO single handedly carrying my portfolio lol
0 · Reply
StockMacroView
StockMacroView May. 4 at 8:49 PM
$NVO is reshaping the GLP-1 narrative. Oral Wegovy launched in Jan → rapid uptake, tens of thousands of patients already, many first-time users. Telehealth demand reportedly doubled early on. Vs $LLY oral rollout still slower (~20K starts, ~1K/day adds). $NVO leveraged $149/month pricing + near-injection efficacy + brand power to dominate early perception. Orals = market expansion, not just substitution. Still early, volatile, but direction is clear: the oral GLP-1 race is heating up fast. Free sharing and subscription 👉 @StockMacroView.
0 · Reply
Hooooooold
Hooooooold May. 4 at 8:42 PM
$NVO nice! Ozempic tablets are available in 1.5mg, 4mg, and 9mg doses, starting on 4 May and Novo Nordisk has also filed for FDA approval for a 25mg Ozempic tablet, with a decision expected by the end of 2026.
0 · Reply
Hooooooold
Hooooooold May. 4 at 8:36 PM
$NVO The three Catalent fill-finish sites acquired by [[Novo Nordisk]] (in Bloomington, IN; Brussels, Belgium; and Anagni, Italy) are designed to "significantly" increase manufacturing capacity for GLP-1 and diabetes treatments, supporting a portion of the 45.2 million people Novo Nordisk served globally in 2024
0 · Reply
LowerLimb
LowerLimb May. 4 at 8:35 PM
$NVO bought back my CCs, you can feel the energy shifting
0 · Reply
alwayzwong
alwayzwong May. 4 at 8:16 PM
$NVO get ready for the push NORTH
0 · Reply
FlyingTargets
FlyingTargets May. 4 at 8:10 PM
$RVI $CHWY $NVO nord
0 · Reply
alwayzwong
alwayzwong May. 4 at 8:06 PM
$NVO well, gap is closing soon.
0 · Reply
jvitalis
jvitalis May. 4 at 7:57 PM
$NVO Timber!
1 · Reply
JFais
JFais May. 4 at 7:49 PM
$XBI $NVO $ABCL
0 · Reply
ChipDistribution7
ChipDistribution7 May. 4 at 7:41 PM
$NOW down ~60% from ATH 📉 Trading below 2W 200 EMA Sitting inside a key higher-timeframe Fib zone Structurally, this is starting to look like the kind of area where longer-term reversals can form — similar setup vibes to what we saw with $NVO before it stabilized. But key question here: 👉 Is this a true accumulation zone… or just another lower-high before continuation down? Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!
1 · Reply
RonSymons
RonSymons May. 4 at 7:21 PM
Brazil has approved $NVO’s highest dose of Wegovy at 7.2 mg for obesity treatment. The indication is for patients with a BMI above 30, targeting individuals requiring greater weight reduction. This approval follows earlier clearances in the US and Europe, further expanding access to higher-efficacy GLP-1 treatment options in a key market.
0 · Reply
Plowmaster
Plowmaster May. 4 at 7:06 PM
$NVO setup into earnings looking real interesting here. Stock’s been beat down on “Lilly taking over” narrative but latest data not backing that up. Lilly’s oral launch tracking weaker than expected vs Wegovy, and even some early safety noise floating around. Meanwhile Wegovy still dominating real-world adoption. Now layer that with: * oversold technicals * analysts calling for rebound * sentiment reset If earnings come in clean with solid guidance, this is exactly the type of setup that can squeeze hard. I’m positioned across stock + near-term + June options. Not financial advice. Do your own DD.
1 · Reply
topstockalerts
topstockalerts May. 4 at 6:48 PM
Novo’s Wegovy pill uses the same main ingredient as its weekly shot. The company had at times struggled to produce enough of the peptide to satisfy the soaring demand for the injection, and the oral formulation required even more of it. Meanwhile, Lilly was telling investors its GLP-1 pill was easier to make and wouldn’t face the shortages that hindered the shots. Doubts about Lilly’s lock on the market emerged last summer when the company said its pill helped people lose about 12% of their body weight, on average. Seigerman noticed Novo pounced on the opportunity and started to highlight the efficacy of oral semaglutide, the active ingredient in Novo’s Wegovy, which delivered almost 17% weight loss in a separate trial. When the Wegovy pill was approved around the New Year, Novo and its telehealth partners rolled out a high-profile promotional blitz. Ads blanketed New York City subways and TV broadcasts. $NVO
0 · Reply
topstockalerts
topstockalerts May. 4 at 6:47 PM
When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight. LifeMD went from seeing between 300 and 400 new patients a day to 600 to 1,000 new patients a day, said CEO Justin Schreiber. He knew there would be demand, but that level of interest surprised him. “There’s no question that the launch of oral medications has improved access,” Schreiber said. Tens of thousands of people have started taking Novo Nordisk’s Wegovy pill in the four months since it launched in the U.S., the majority of them new to the GLP-1 category. Investors will get a fresh look at the Wegovy pill’s momentum when Novo reports first-quarter results on Wednesday. $NVO
0 · Reply
alwayzwong
alwayzwong May. 4 at 6:35 PM
$NVO oh, from the Endo board. How’s it going?
0 · Reply
Alexhere
Alexhere May. 4 at 6:25 PM
$NVO https://www.pharmaceutical-technology.com/news/novo-nordisk-to-launch-ozempic/
0 · Reply